Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT
-
Oct 9, 2026, 07:00Danny Reardon: Closing the Global Awareness Gap on Blood Clots
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit